Melissa Joan Hart discusses the groundbreaking legacy of "Clarissa Explains It All."
Melissa Joan Hart discusses the groundbreaking legacy of "Clarissa Explains It All."
Moderna Inc. said it would ask U.S. and European regulators Monday to allow emergency use of its COVID-19 vaccine as new study results confirm the shots offer strong protection — ramping up the race to begin limited vaccinations as the coronavirus rampage worsens. Multiple vaccine candidates must succeed for the world to stamp out the pandemic, which has been on the upswing in the U.S. and Europe. U.S. hospitals have been stretched to the limit as the nation has seen more than 160,000 new cases per day and more than 1,400 daily deaths.
Police in Argentina have opened an investigation to determine the part played by Diego Maradona's surgeon, Leopoldo Luque, in the football legend's death last week at the age of 60. Leopoldo Luque responded to the launch of the investigation for involuntary manslaughter by saying he had done "everything he could, up to the impossible" for an "unmanageable" patient.Prosecutors in San Isidro, near Buenos Aires, said they were investigating Luque, while Argentine television showed police raiding the doctor's surgery and home.A statement from the prosecutors' office later said they had begun analysing material gathered and clarified that "no decisions have been made at the moment regarding the procedural situation of any person".Daughters concerned about treatmentThe probe was triggered by concerns raised by Maradona's daughters Dalma, Gianinna and Jana over the treatment he received for his heart condition at his home in Tigre, north of Buenos Aires, judicial sources said.Maradona died of a heart attack on Wednesday aged 60, and was buried on Thursday at the Jardin de Paz cemetery on the outskirts of the Argentine capital."Our investigations are ongoing, we are talking to witnesses including members of the family," a source close to the San Isidro inquiry said."The clinic had recommended that he go elsewhere to be hospitalised, but the family decided otherwise. His daughters signed for him to be discharged from the hospital," said a family member.Emotional news conferenceLater in the day, Luque, who is no relation to Maradona's former Argentina team-mate of the same name, gave an emotional televised news conference."You want to know what I am responsible for?" the 39-year-old doctor asked between sobs. "For having loved him, for having taken care of him, for having extended his life, for having improved it to the end."Luque said he did "everything he could, up to the impossible" and considered himself a "friend" of Maradona and saw him "as a father, not as a patient".Luque had posted a photograph of himself with Maradona when the former player left hospital on 12 November, eight days after the doctor operated to remove a brain blood clot. Maradona returned home to Tigre where he received round-the-clock medical care and could remain close to his daughters."He should have gone to a rehabilitation centre. He didn't want to," said Luque who called Maradona "unmanageable".
Vast Resources plc / Ticker: VAST / Index: AIM / Sector: Mining 30 November 2020 Vast Resources plc(‘Vast’ or the ‘Company’) Progress on asset backed debt finance Vast Resources plc, the AIM-listed mining company, is pleased to confirm that it has received the detailed facility agreement from the international banking institution (the ‘Bank’) in relation to the previously announced asset backed debt financing linked to Vast’s now 100% owned Baita Plai Polymetallic Mine (‘Baita Plai’) in Romania. The facility agreement, to be finalised between Vast and the Bank, will be presented to the Bank’s credit committee for final approval in a meeting that is scheduled for 15 December 2020. Andrew Prelea, CEO of Vast Resources PLC commented: “The detailed facility agreement for the asset backed debt facility is an important milestone for Vast. The recommencement of mining at Baita Plai, the completion of the first commercial sale of copper concentrate, and the recent acquisition of the remaining 20% interest in Baiti Plai to give Vast 100% ownership and control of the mine, have all paved the way for us to reach this point. We look forward to securing final approval for the facility agreement and growing the Company as a low cost copper and polymetallic producer with the support of our new banking partner.” **ENDS** For further information, visit www.vastplc.com or please contact: Vast Resources plc Andrew Prelea (Chief Executive Officer)Andrew Hall www.vastplc.com +44 (0) 20 7846 0974Beaumont Cornish - Financial & Nominated Adviser Roland Cornish James Biddle www.beaumontcornish.com +44 (0) 020 7628 3396SP Angel Corporate Finance LLP – Joint Broker Richard Morrison Caroline Rowe www.spangel.co.uk +44 (0) 20 3470 0470 Axis Capital Markets Limited – Joint Broker Richard Hutchison www.axcap247.com +44 (0) 20 3206 0320St Brides Partners Limited Susie Geliher Charlotte Page www.stbridespartners.co.uk +44 (0) 20 7236 1177 The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 (“MAR”). ABOUT VAST RESOURCES PLC Vast Resources plc is a United Kingdom AIM listed mining company with mines and projects in Romania and Zimbabwe. In Romania, the Company is focused on the rapid advancement of high-quality projects by recommencing production at previously producing mines. The Company’s Romanian portfolio includes an 100% interest in the producing Baita Plai Polymetallic Mine, located in the Apuseni Mountains, Transylvania, an area which hosts Romania’s largest polymetallic mines. The mine has a JORC compliant Reserve & Resource Report which underpins the initial mine production life of approximately 3-4 years with an in-situ total mineral resource of 15,695 tonnes copper equivalent with a further 1.8M–3M tonnes exploration target. The Company is now working on confirming an enlarged exploration target of up to 5.8M tonnes. The Company also owns the Manaila Polymetallic Mine in Romania, which was commissioned in 2015, currently on care and maintenance. The Company has been granted the Manaila Carlibaba Extended Exploitation Licence that will allow the Company to re-examine the exploitation of the mineral resources within the larger Manaila Carlibaba licence area. In Zimbabwe, the Company is focused on the commencement of the joint venture mining agreement on the Community Diamond Concession, Chiadzwa, in the Marange Diamond Fields.
Oak Street Health Announces Participation at Piper Sandler 32nd Annual Virtual Healthcare Conference
Angus Reid Institute and Clear Seas Centre study reveals what Canadians think about marine shipping and its role in post COVID-19 economic recovery.
WiSA’s first branded product, SoundSend audio transmitter, now available for WiSA partners, distributors and retailers
On Tuesday, Dec. 1, Los Angeles’ top rated morning radio show, The Ellen K Morning Show on KOST 103.5, will help kick off the season of giving with the Children’s Hospital Los Angeles (CHLA) annual Giving Tuesday fundraising campaign. Giving Tuesday is the international day of charitable giving that takes place on the first Tuesday after Thanksgiving.
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the completion of its target enrollment in the INTRIGUE Phase 3 clinical study evaluating the efficacy and safety of QINLOCK in patients with second-line gastrointestinal stromal tumor (GIST). QINLOCK, the Company’s switch-control tyrosine kinase inhibitor, is currently approved in the U.S., Canada, and Australia for patients with fourth-line GIST.
Tecnológico de Monterrey has moved up 3 places in the rankings of top universities for entrepreneurship. In 6 years, it has gone from 23rd to 5th place in "The Princeton Review: Top Undergraduate Schools for Entrepreneurship Ranking 2021," published by The Princeton Review and Entrepreneur Magazine.
Antibe Therapeutics Announces TSX Approval and Effective Date of Share Consolidation
Mastercard, TSYS and Extend today introduced a mobile virtual corporate card solution to support for fast and secure contactless payments.
NeoImmuneTech announces the first patient dosed in a Phase 1 study of NT-I7 in adults with mild COVID-19.
Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the initiation of a Phase 2 registration-directed clinical trial of VS-6766, its RAF/MEK inhibitor, and defactinib, its FAK inhibitor, in patients with recurrent low-grade serous ovarian cancer (LGSOC).
Aggressor Adventures®, a leading adventure travel brand, today announces it will expand its adventure offerings with the addition of a bucket list adventure exploring southern Costa Rica with Les Stroud. The new trip explores the "crown jewel" of Costa Rica’s national parks, Corcovado National Park, which is often hailed as one of the most diverse ecosystems in the world
- Findings from the Phase 1 study provide evidence that AUTO6 induces clinical activity in this solid tumor setting without inducing on-target off-tumor toxicity - AUTO6NG builds on this approach utilizing the same GD2 CAR alongside additional programming modules to enhance the efficacy and persistence, expected to enter the clinic in 2021 LONDON, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces publication of AUTO6 (1RG-CAR T) Phase 1 data in Science Translational Medicine. AUTO6 is a second generation GD2-targeting CAR T candidate, developed in collaboration with UCL, and the trial was sponsored and run by Cancer Research UK’s Centre for Drug Development. These new results highlight that AUTO6 can induce rapid regression of bulky disease in a solid tumor setting without inducing on-target off-tumor toxicity, despite dose dependent CAR T expansion. CAR T cell expansion was observed in all six patients treated at the higher cell dose cohorts in this Phase 1 study. Three of these six patients demonstrated evidence of transient CAR T cell activity, including cytokine release syndrome, and regression of soft tissue and bone marrow disease activity. The GD2 binder used in AUTO6 has been designed to minimize on-target off-tumor neurotoxicity associated with GD2 expression at low levels in pain fibers and the brain. Despite the presence of clear CAR T cell activity, no neurotoxicity was observed. The publication also suggests that, whilst AUTO6 is a valid and safe strategy for targeting neuroblastoma, further modifications are required to promote CAR T cell persistence and induce deeper and more durable responses for these patients. “We are encouraged by the anti-tumor activity in neuroblastoma, a disease where there are limited therapeutic options for children with relapsed or refractory disease,” said Dr Karin Straathof, Consultant Paediatric Oncologist and research group leader at UCL Great Ormond Street Institute for Child Health. “This is of particular importance as this activity was observed in the absence of neurotoxicity which occurs with antibody-based approaches that target GD2.” Nigel Blackburn, director of drug development at Cancer Research UK, said, “Children who have hard to treat, or relapsed cancer have limited treatment options open to them, and early results of AUTO6 are encouraging. We look forward to seeing the next steps in the development of AUTO6NG, and if the treatment has durable effects in neuroblastoma.” “This is amongst the clearest data which demonstrate that CAR T cells can be highly active against advanced solid cancers,” said Dr Martin Pule, CSO and founder of Autolus and director of the UCL CAR T programme. “It is encouraging that highly active CAR T cells do not cause on-target off-tumor neurotoxicity and the findings represent an important step in our ongoing efforts to develop CAR T cell therapies for solid cancers.” These data support Autolus’ continued development of AUTO6NG, which builds on this approach utilizing the same GD2 CAR alongside additional programming modules designed to enhance efficacy and persistence. Earlier this year at the American Association for Cancer Research (AACR) meeting, Autolus announced a preclinical data update demonstrating the validity of GD2 as a CAR T target in small cell lung cancer (SCLC) and the ability of Autolus’ efficacy-enhancing modules to drive in vivo efficacy in an SCLC mouse model. The data also suggested AUTO6NG can overcome the immune suppressive mechanisms in the tumor microenvironment. Autolus plans to test AUTO6NG in a Phase 1 study in 2021. About Autolus Therapeutics plcAutolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defence mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumors. For more information please visit www.autolus.com. About UCL Business PLCUCL Business PLC (UCLB) is a leading technology transfer company that supports and commercialises research and innovations arising from UCL, one of the UK’s top research-led universities. UCLB has a successful track record and a strong reputation for identifying and protecting promising new technologies and innovations from UCL academics. UCLB has a strong track record in commercialising medical technologies and provides technology transfer services to UCL’s associated hospitals; University College London Hospitals, Moorfields Eye Hospital, Great Ormond Street Hospital for Children and the Royal Free London Hospital. It invests directly in development projects to maximise the potential of the research and manages the commercialisation process of technologies from laboratory to market. For further information, please visit: www.uclb.com Twitter: @UCL_Business About Cancer Research UK Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research.Cancer Research UK’s pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last 40 years.Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK’s ambition is to accelerate progress so that by 2034, 3 in 4 people will survive their cancer for at least 10 years.Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured. For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit www.cancerresearchuk.org. Follow us on Twitter and Facebook. About NeuroblastomaNeuroblastoma is the most common solid tumor in children that occurs outside of the brain and makes up 8% of the total number of children’s cancers. The site of origin is either in one of the two adrenal glands situated in the abdomen or in nerve tissue that runs alongside the spinal cord, in the neck, chest, abdomen or pelvis. The adrenal glands normally release hormones to maintain blood pressure and enable the body to respond to stress. In up to half of patients diagnosed with neuroblastoma, the tumor has spread to tissues beyond the original site such as the bone marrow, bone, lymph nodes, liver, and skin. As with most cancers, the cause of neuroblastoma is not known. When the lesion is localised, it is generally curable. However, long-term survival for children with advanced disease older than 18 months of age is poor despite aggressive multimodal therapy. About AUTO6NGAUTO6NG is a next generation programmed T cell product candidate in pre-clinical development. AUTO6NG builds on preliminary proof of concept data from AUTO6, a CAR targeting GD2-expression cancer cell currently in clinical development for the treatment of neuroblastoma. AUTO6NG incorporates additional cell programming modules to overcome immune suppressive defence mechanisms in the tumor microenvironment, in addition to endowing the CAR T cells with extended persistence capacity. AUTO6NG is currently in preclinical development for the potential treatment of both neuroblastoma and other GD2-expressing solid tumors, including osteosarcoma, soft tissue sarcoma, small cell lung cancer, and melanoma. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding Autolus’ financial condition and results of operations, including its expected cash runway; the development of Autolus’ product candidates, including statements regarding the timing of initiation, completion and the outcome of pre-clinical studies or clinical trials and related preparatory work, and the periods during which the results of the studies and trials will become available; Autolus’ plans to research, develop, manufacture and commercialize its product candidates; the potential for Autolus’ product candidates to be alternatives in the therapeutic areas investigated; and Autolus’ manufacturing capabilities and strategy. Any forward-looking statements are based on management's current views and assumptions and involve risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section titled "Risk Factors" in Autolus' Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 3, 2020 as well as discussions of potential risks, uncertainties, and other important factors in Autolus' future filings with the Securities and Exchange Commission from time to time. All information in this press release is as of the date of the release, and the company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law. Contact: Lucinda Crabtree, PhDVice President, Investor Relations and Corporate Communications+44 (0) 7587 372 firstname.lastname@example.org Julia Wilson+44 (0) 7818 email@example.com Susan A. NoonanS.A. Noonan Communicationsfirstname.lastname@example.org
Marimekko Corporation, Press release, 30 November 2020 at 2.00 p.m. As part of its fall 2021 collection, Marimekko will launch its first garments, bags and home items that are printed with a natural dye. The blue shade of the fabrics is the result of collaboration with Natural Indigo Finland, a Finnish company concentrating on natural dyes. Marimekko and Natural Indigo Finland began their collaboration on the industrial use of natural dyes in August 2019. Marimekko’s printing factory in Helsinki has, among other things, been involved in developing the recipe for the blue dye obtained from the woad plant as well as testing the fastness of the dye in use. “It is important for Marimekko to be involved in finding and developing new, more sustainable material solutions for the future, among other things. Our own printing factory in Helsinki offers unique possibilities for testing new fabrics and dyestuffs in the printing process. We are very pleased that, together with Natural Indigo, we have been able to bring a natural indigo dye into use on an industrial scale,” says Minna Kemell-Kutvonen, Marimekko’s Director of Home and Print Design. “We continuously aim to increase the share of sustainable cotton as well as of other more sustainable materials in our products and packaging and to find more environmentally-friendly alternatives to the substances used in the manufacturing processes. The use of natural dyes in textile printing is a very interesting option. It is always a pleasure to find good Finnish partners and together develop solutions that can bring the whole industry forward.” The following items printed with a blue dye obtained from woad will hit the stores in July 2021: Norkko shirts and cotton purses featuring the iconic Unikko design, classic striped Jokapoika shirts as well as fabric, cushion covers and bags in the Silkkikuikka pattern. “The aim of Natural Indigo is to produce dyes sustainably and ethically and so offer the textile industry one way of enhancing sustainability. I am glad that Marimekko early on wanted to engage in this project and participate in furthering the use of natural dyes on an industrial scale,” says Pasi Ainasoja from Natural Indigo Finland. The industrial use of dyes derived from nature is only in its early stages, but the products to be launched as a result of this collaboration prove that natural dyes are an interesting option for textile printing in the future. In addition to the indigo dye obtained from woad, Natural Indigo Finland has also tested extracting yellow, green and gray dyes, for example, from various industry by-products, such as onion skins. The use of natural dyes requires new thinking about pattern design and coloring, as growth conditions, among other things, affect how the color appears on fabric. Also, it is characteristic of indigo obtained from woad, as of all natural dyes, that the intensity of the color changes with washing and use. The launch of the products printed with a natural indigo dye will take place in the 70th anniversary year of Marimekko. Through the decades, Marimekko has remained true to its original mission of bringing joy to life with bold prints and colors. During the whole anniversary year, Marimekko’s prints and colors will be in the limelight. Pictures of the products are available on Marimekko Media Bank: https://mediabank.marimekko.fi/l/K-T_6_7L5gx6 Further information: Asta Halme, Marimekko Communications, tel. +358 9 7587 233 / email@example.com Pasi Ainasoja, Natural Indigo Finland, tel. +358 40 028 2370 / firstname.lastname@example.org DISTRIBUTION: Key media Marimekko is a Finnish lifestyle design company renowned for its original prints and colors. The company’s product portfolio includes high-quality clothing, bags and accessories as well as home décor items ranging from textiles to tableware. When Marimekko was founded in 1951, its unparalleled printed fabrics gave it a strong and unique identity. Marimekko products are sold in about 40 countries. In 2019, brand sales of the products worldwide amounted to EUR 251 million and the company's net sales were EUR 125 million. Roughly 150 Marimekko stores serve customers around the globe. The key markets are Northern Europe, North America and the Asia-Pacific region. The Group employs about 450 people. The company’s share is quoted on Nasdaq Helsinki Ltd. www.marimekko.com Natural Indigo Finland produces natural dyes in Nivala, Northern Finland, for the textile industry, among others. The main product of Natural Indigo is a blue dye extracted from the leaves of the woad plant cultivated by the company. Natural Indigo has also developed woad cultivation and dye production as part of the international multidisciplinary BioColour project. www.naturalindigo.fi
Piper Sandler Expands Public Finance Investment Banking with the Addition of Special District Group
Sherritt International Corporation ("Sherritt" or "the Corporation") (TSX:S), a world leader in the mining and refining of nickel and cobalt from lateritic ores, today announced that it has renewed and extended its $70 million credit facility with its syndicate of lenders to April 30, 2022. The renewal builds on the Corporation’s recently completed balance sheet initiative and related efforts to strengthen its capital structure and improve its liquidity.
Kinaset Therapeutics, Inc. ("Kinaset" or the "Company"), a newly-founded biopharmaceutical company, today announced a $40 million Series A financing with a blue-chip investor syndicate of 5AM Ventures, Atlas Venture, and Gimv. The Company also announced an exclusive global in-license and services agreement with Vectura Group plc (LSE: VEC) ("Vectura") to develop and commercialize KN-002 (formerly known as VR588), a novel, inhaled small-molecule pan-JAK inhibitor, for the treatment of eosinophilic and non-eosinophilic severe asthma. A Phase 1/1b clinical trial in healthy volunteers and patients is poised to begin in the first half of 2021.
PureTech to Host Virtual R&D Day for Investors on December 11, 2020